Table 1.
Clinical characteristics of SIBDC patients with ulcerative colitis (UC), treated with golimumab, other anti-TNF medication, or without any anti-TNF treatment.
| Golimumab | Other anti-TNF | No anti-TNF | p value chi2 or Kruskal–Wallis test | |
|---|---|---|---|---|
| Number of patients | 109 (6.2%) | 572 (32.3%) | 1088 (61.5%) | — |
| Gender | ||||
| Male | 52 (47.7%) | 317 (55.4%) | 569 (52.3%) | 0.248 |
| Female | 57 (52.3%) | 255 (44.6%) | 519 (47.7%) | |
| Age at diagnosis | ||||
| Median, IQR, | 27.0, 20.6 – 35.5, | 26.5, 18.9 – 37.1, | 29.4, 19.7 – 40.2, | 0.025 |
| Min–max | 10.3 – 70.5 | 2.5 – 72.2 | 0.8 – 85.5 | |
| Disease duration | ||||
| Median, IQR, | 10.7, 8.2 – 18.1, | 11.0, 6.4 – 17.1, | 11.7, 5.9 – 19.7, | 0.343 |
| Min–max | 0.2 – 41.5 | 0.3 – 44.2 | 0.1 – 54.2 | |
| Maximal MTWAI | ||||
| Median, IQR, | 7, 4 – 10, | 6, 3 – 9, | 3, 2 – 6, | < 0.001 |
| Min–max | 0 – 19 | 0 – 18 | 0 – 18 | |
| Initial location | ||||
| Proctitis | 20 (20.0%) | 68 (13.1%) | 268 (27.1%) | < 0.001 |
| Left-sided colitis | 36 (36.0%) | 179 (34.4%) | 317 (32.0%) | |
| Pancolitis | 44 (44.0%) | 273 (52.5%) | 405 (40.9%) | |
| Unknown | 9 | 52 | 98 | |
| Maximal extent | ||||
| Proctitis | 4 (3.7%) | 21 (3.7%) | 141 (13.3%) | < 0.001 |
| Left-sided colitis | 31 (28.4%) | 130 (22.9%) | 334 (31.4%) | |
| Pancolitis | 74 (67.9%) | 417 (73.4%) | 587 (55.3%) | |
| Unknown | 0 | 4 | 26 | |
| Occurrence of | ||||
| EIM | 61 (56.0%) | 276 (48.3%) | 363 (33.4%) | < 0.001 |
| Complication | 73 (67.0%) | 372 (65.0%) | 494 (45.4%) | < 0.001 |
| Intestinal surgery | 16 (14.7%) | 80 (14.0%) | 83 (7.6%) | < 0.001 |
| Any surgery | 30 (27.5%) | 150 (26.2%) | 204 (18.8%) | 0.001 |
Source: SIBDC database. Please note that our chart review confirmed UC diagnosis and golimumab treatment only in 103 of 109 patients.
EIM, extraintestinal manifestation; IQR, interquartile range; MTWAI, modified Truelove and Witts activity index; SIBDC, Swiss Inflammatory Bowel Disease Cohort; TNF, tumor necrosis factor.